This CHMP position statement replaces the CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products (EMA/CHMP/BWP/303353/2010).
Keywords: Creutzfeldt-Jakob disease, human transmissible spongiform encephalopathies, plasma-derived medicinal products, urine-derived medicinal products, sporadic CJD, genetic CJD, iatrogenic CJD, variant CJD, blood infectivity, transmissibility
Current version
CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3
Document history - Revision 2
CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2
Overview of comments received on 'Committee for Medicinal Products for Human Use position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products'
Draft CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2
Document history - Revision 1
Concept paper on the need to update the CHMP position statement on CJD and plasma-derived and urine-derived medicinal products (EMEA/CPMP/BWP/2879/02 REV. 1)
CHMP position statement on Creutzfeldt-Jacob disease and plasma-derived and urine-derived medicinal products - Revision 1
Document history - First version
CPMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - First version
CPMP position statement on new variant CJD and plasma-derived medicinal products - Superseded by CPMP/BWP/2879/02